Standard

Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy. / Sato, Eisuke; Zaboronok, Alexander; Yamamoto, Tetsuya et al.

In: Journal of Radiation Research, Vol. 59, No. 2, 01.03.2018, p. 101-107.

Research output: Contribution to journalArticlepeer-review

Harvard

Sato, E, Zaboronok, A, Yamamoto, T, Nakai, K, Taskaev, S, Volkova, O, Mechetina, L, Taranin, A, Kanygin, V, Isobe, T, Mathis, BJ & Matsumura, A 2018, 'Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy', Journal of Radiation Research, vol. 59, no. 2, pp. 101-107. https://doi.org/10.1093/jrr/rrx071

APA

Sato, E., Zaboronok, A., Yamamoto, T., Nakai, K., Taskaev, S., Volkova, O., Mechetina, L., Taranin, A., Kanygin, V., Isobe, T., Mathis, B. J., & Matsumura, A. (2018). Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy. Journal of Radiation Research, 59(2), 101-107. https://doi.org/10.1093/jrr/rrx071

Vancouver

Sato E, Zaboronok A, Yamamoto T, Nakai K, Taskaev S, Volkova O et al. Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy. Journal of Radiation Research. 2018 Mar 1;59(2):101-107. doi: 10.1093/jrr/rrx071

Author

Sato, Eisuke ; Zaboronok, Alexander ; Yamamoto, Tetsuya et al. / Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy. In: Journal of Radiation Research. 2018 ; Vol. 59, No. 2. pp. 101-107.

BibTeX

@article{47ba306706044454a6f374e88c49891a,
title = "Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy",
abstract = "In the current article, we provide in vitro efficacy evaluation of a unique accelerator-based neutron source, constructed at the Budker Institute of Nuclear Physics (Novosibirsk, Russian Federation), for boron neutron capture therapy (BNCT), which is particularly effective in the case of invasive cancers. U251MG, CHO-K1 and V79 cells were incubated and irradiated in various concentrations of boric acid with epithermal neutrons for 2–3 h in a plexiglass phantom, using 2.0 MeV proton energy and 1.5–3.0 mA proton current, resulting in a neutron fluence of 2.16 × 1012 cm−2. The survival curves of cells loaded with boron were normalized to those irradiated without boron (to exclude the influence of the fast neutron and gamma dose components) and fit to the linear–quadratic (LQ) model. Colony formation assays showed the following cell survival rates (means ± SDs): CHO-K1: 0.348 ± 0.069 (10 ppm), 0.058 ± 0.017 (20 ppm), 0.018 ± 0.005 (40 ppm); V79: 0.476 ± 0.160 (10 ppm), 0.346 ± 0.053 (20 ppm), 0.078 ± 0.015 (40 ppm); and U251MG: 0.311 ± 0.061 (10 ppm), 0.131 ± 0.022 (20 ppm), 0.020 ± 0.010 (40 ppm). The difference between treated cells and controls was significant in all cases (P < 0.01) and confirmed that the neutron source and irradiation regimen were sufficient for control over cell colony formation. We believe our study will serve as a model for ongoing in vitro experiments on neutron capture therapy to advance in this area for further development of accelerator-based BNCT into the clinical phase.",
keywords = "Accelerator-based neutron source, Boric acid, Boron neutron capture therapy, In vitro efficacy evaluation, Lithium target, boric acid, TARGET, TSUKUBA, boron neutron capture therapy, BNCT, lithium target, NECK-CANCER, accelerator-based neutron source, NANOPARTICLES, IN-VITRO, GLIOBLASTOMA, TRANSPORT, RECURRENT HEAD, in vitro efficacy evaluation",
author = "Eisuke Sato and Alexander Zaboronok and Tetsuya Yamamoto and Kei Nakai and Sergey Taskaev and Olga Volkova and Ludmila Mechetina and Alexander Taranin and Vladimir Kanygin and Tomonori Isobe and Mathis, {Bryan J.} and Akira Matsumura",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2017.",
year = "2018",
month = mar,
day = "1",
doi = "10.1093/jrr/rrx071",
language = "English",
volume = "59",
pages = "101--107",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Radiobiological response of U251MG, CHO-K1 and V79 cell lines to accelerator-based boron neutron capture therapy

AU - Sato, Eisuke

AU - Zaboronok, Alexander

AU - Yamamoto, Tetsuya

AU - Nakai, Kei

AU - Taskaev, Sergey

AU - Volkova, Olga

AU - Mechetina, Ludmila

AU - Taranin, Alexander

AU - Kanygin, Vladimir

AU - Isobe, Tomonori

AU - Mathis, Bryan J.

AU - Matsumura, Akira

N1 - Publisher Copyright: © The Author(s) 2017.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - In the current article, we provide in vitro efficacy evaluation of a unique accelerator-based neutron source, constructed at the Budker Institute of Nuclear Physics (Novosibirsk, Russian Federation), for boron neutron capture therapy (BNCT), which is particularly effective in the case of invasive cancers. U251MG, CHO-K1 and V79 cells were incubated and irradiated in various concentrations of boric acid with epithermal neutrons for 2–3 h in a plexiglass phantom, using 2.0 MeV proton energy and 1.5–3.0 mA proton current, resulting in a neutron fluence of 2.16 × 1012 cm−2. The survival curves of cells loaded with boron were normalized to those irradiated without boron (to exclude the influence of the fast neutron and gamma dose components) and fit to the linear–quadratic (LQ) model. Colony formation assays showed the following cell survival rates (means ± SDs): CHO-K1: 0.348 ± 0.069 (10 ppm), 0.058 ± 0.017 (20 ppm), 0.018 ± 0.005 (40 ppm); V79: 0.476 ± 0.160 (10 ppm), 0.346 ± 0.053 (20 ppm), 0.078 ± 0.015 (40 ppm); and U251MG: 0.311 ± 0.061 (10 ppm), 0.131 ± 0.022 (20 ppm), 0.020 ± 0.010 (40 ppm). The difference between treated cells and controls was significant in all cases (P < 0.01) and confirmed that the neutron source and irradiation regimen were sufficient for control over cell colony formation. We believe our study will serve as a model for ongoing in vitro experiments on neutron capture therapy to advance in this area for further development of accelerator-based BNCT into the clinical phase.

AB - In the current article, we provide in vitro efficacy evaluation of a unique accelerator-based neutron source, constructed at the Budker Institute of Nuclear Physics (Novosibirsk, Russian Federation), for boron neutron capture therapy (BNCT), which is particularly effective in the case of invasive cancers. U251MG, CHO-K1 and V79 cells were incubated and irradiated in various concentrations of boric acid with epithermal neutrons for 2–3 h in a plexiglass phantom, using 2.0 MeV proton energy and 1.5–3.0 mA proton current, resulting in a neutron fluence of 2.16 × 1012 cm−2. The survival curves of cells loaded with boron were normalized to those irradiated without boron (to exclude the influence of the fast neutron and gamma dose components) and fit to the linear–quadratic (LQ) model. Colony formation assays showed the following cell survival rates (means ± SDs): CHO-K1: 0.348 ± 0.069 (10 ppm), 0.058 ± 0.017 (20 ppm), 0.018 ± 0.005 (40 ppm); V79: 0.476 ± 0.160 (10 ppm), 0.346 ± 0.053 (20 ppm), 0.078 ± 0.015 (40 ppm); and U251MG: 0.311 ± 0.061 (10 ppm), 0.131 ± 0.022 (20 ppm), 0.020 ± 0.010 (40 ppm). The difference between treated cells and controls was significant in all cases (P < 0.01) and confirmed that the neutron source and irradiation regimen were sufficient for control over cell colony formation. We believe our study will serve as a model for ongoing in vitro experiments on neutron capture therapy to advance in this area for further development of accelerator-based BNCT into the clinical phase.

KW - Accelerator-based neutron source

KW - Boric acid

KW - Boron neutron capture therapy

KW - In vitro efficacy evaluation

KW - Lithium target

KW - boric acid

KW - TARGET

KW - TSUKUBA

KW - boron neutron capture therapy

KW - BNCT

KW - lithium target

KW - NECK-CANCER

KW - accelerator-based neutron source

KW - NANOPARTICLES

KW - IN-VITRO

KW - GLIOBLASTOMA

KW - TRANSPORT

KW - RECURRENT HEAD

KW - in vitro efficacy evaluation

UR - http://www.scopus.com/inward/record.url?scp=85052016832&partnerID=8YFLogxK

U2 - 10.1093/jrr/rrx071

DO - 10.1093/jrr/rrx071

M3 - Article

C2 - 29281044

AN - SCOPUS:85052016832

VL - 59

SP - 101

EP - 107

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 2

ER -

ID: 16104983